18th Jan 2016 08:42
LONDON (Alliance News) - Regenerative medical devices company Tissue Regenix Group PLC on Monday said it has now completed the enrolment process for its OrthoPure clinical trial.
The final operation took place on Friday in Valencia, Spain, and the 20 patients involved in the trial will now be monitored for six months post-operation.
"We are delighted to announce the completion of enrolment for the OrthoPure XM clinical trial. The strict selection criteria meant that there was only a small pool of patients which could be considered to validate the safety and success of the treatment," said Peter Hamer, Tissue Regenix's orthopaedics commercial director.
Shares in Tissue Regenix were down 0.7% to 13.40 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group